Soft Tissue clinical trials

Explore recruiting soft tissue clinical trials.

Recruiting soft tissue studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Soft Tissue trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized Soft Tissue Sarcoma

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

Belgium, Finland, France, Germany, Netherlands, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

Spain, France, Germany, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone, and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or, easily injectable lymph nodes of metastatic/advanced solid tumors.

Belgium, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Adjunctive Hyperbaric Oxygen Treatment for Patients with Necrotizing Soft-Tissue Infection (HOT-NSTI trial)

Sweden, Finland, Belgium, Norway, Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Soft Tissue trials by city

Soft Tissue in Toronto Soft Tissue in Vancouver Soft Tissue in Montreal Soft Tissue in Calgary Soft Tissue in Edmonton Soft Tissue in Ottawa Soft Tissue in Winnipeg Soft Tissue in Quebec City Soft Tissue in Hamilton Soft Tissue in Kitchener Soft Tissue in London Soft Tissue in Halifax Soft Tissue in New York Soft Tissue in Los Angeles Soft Tissue in Chicago Soft Tissue in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease